Breast Cancer Research Studies
BR003: A Randomized Phase III Trial of Adjuvant Therapy
Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with
or without Carboplatin for Node-Positive or High-Risk Node-Negative
Triple-Negative Invasive Breast Cancer.
WO39391: A Phase III, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in
Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus
Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer
NODE+ / HIGH RISK NODE - / HER2-
A011502: A Randomized Phase III Double-Blinded
Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive HER2
Negative Breast Cancer: The ABC Trial.
EA1181: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered
Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory
BR004: A Randomized, Double-Blind, Phase III Trial of
Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line
HER2-Positive Metastatic Breast Cancer
A011202: A Randomized Phase III Trial Comparing Axillary
Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3N1)
who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.
B-51: A Randomized Phase III Clinical Trial Evaluating
Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional
Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant
Chemotherapy who Convert to Pathologically Negative Axillary Nodes After
EA1131: A Randomized Phase III Post-Operative Trial of
Platinum-Based Chemotherapy Vs. Capecitabine in Patients with Residual
Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy.
S1418: A Randomized Phase III Trial to Evaluate the
Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple
Receptor-Negative Breast Cancer with ≥ 1cm Residual Invasive Cancer or Positive
Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
A011404: Randomized Phase III Trial Evaluating the Role
of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early
A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy
Radiation with Breast Reconstruction
WF-97116: A Phase 3 Placebo-Controlled Clinical Trial of
Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment